U.S., March 5 -- ClinicalTrials.gov registry received information related to the study (NCT06857214) titled 'A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus' on Feb. 26.
Brief Summary: This study is a randomized, controlled, phase I clinical study with safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics in patients with systemic lupus erythematosus.
Study Start Date: March, 2025
Study Type: INTERVENTIONAL
Condition:
Systemic Lupus Erythematosus
Intervention:
DRUG: GNC-038
Administration by intravenous infusion. Once a week (IV, QW), twice in total.
DRUG: Placebo
The control group will be set up in phase Ib, and an appropriate dose will be selected based on phase ...